Skip to main content
PBLS logo

PBLS · Parabilis Medicines, Inc. · Documents

Track PBLS — free
$28.67 +0.42 (+1.49%)
Market Cap
$3.54B
Shares
125.26M
Volume · Nov 18 198.62K Avg daily vol (3M) 944.98K

The company's filings, earnings calls and investor events, most recent first. Search and read these filings from Claude or ChatGPT with the SEC filings MCP server →

Quarterly report New FY2026 Q3 Revenue $2.11M 10-Q filed Nov 12, 2026 Latest results New Zolucatetide 72.2% response in evaluable ≥450 mg patients 8-K filed Nov 12, 2026
2026
Nov 16
Investor event
Zolucatatide phase 3 set after 72% ORR

Parabilis Medicines, Inc. plans to begin a phase 3 study of zolucatatide in the first half of next year after an FDA end-of-phase 2 meeting cleared the path, following a 72% ORR at 32 weeks in desmoid tumors.

2 source passages
We observed in that tumor type a 72% ORR at 32 weeks. We have met with the FDA at an end of phase 2 meeting and have a clear green light to proceed with phase 3 that we call the pedestal study, and that's slated to start in the first half of next year Open the document at this passage
Nov 12
Quarterly report 10-Q FY2026 Q3, ended Sep 30
Net loss widens to $44.5 million in third quarter

Net loss widened to $44.5 million for the three months ended September 30, 2026, from $33.5 million a year earlier. Research and development expense rose to $45.6 million, mainly from higher external costs for zolucatetide. Cash, cash equivalents and marketable securities totaled $1,072.9 million at September 30, 2026, which the company expects to fund operations into 2030.

Revenue $2.11M Net loss $44.49M Diluted EPS -$0.36
Read from the MD&A section
5 source passages
Our net losses were $44.5 million and $33.5 million for the three months ended September 30, 2026 and 2025, respectively. Research and development expense was $45.6 million for the three months ended September 30, 2026, as compared to $28.2 million for the three months ended September 30, 2025. an increase in external expenses for our lead product candidate, zolucatetide, of $9.7 million, which was primarily attributable to increases in costs incurred for CROs, CMOs and consultants As of September 30, 2026, we had total cash, cash equivalents and marketable securities of $1,072.9 million. We believe that our existing cash, cash equivalents and marketable securities will enable us to fund our operating expenses and capital expenditure requirements into 2030. Open the document at this passage
Nov 12
Current report 8-K
Zolucatetide 72.2% response in evaluable ≥450 mg patients

Parabilis Medicines reported a 72.2% objective response rate at the 32-week landmark among evaluable desmoid-tumor patients receiving a starting dose of ≥450 mg; $1.1 billion in cash, cash equivalents and marketable securities is expected to fund operations into 2030.

Financial results
2 source passages
An objective response rate (ORR) of 72.2% (13/18) among patients evaluable at the 32-week landmark who received a starting dose of ≥450 mg Ended the third quarter with $1.1 billion in cash, cash equivalents and marketable securities, expected to fund operations into 2030 Open the document at this passage
Nov 9
Investor event
Zolucatetide advances toward global Phase Three after strong desmoid results

Parabolus plans to initiate the global pedestal Phase Three study of Zolucatetide in the first half next year, following an FDA-agreed induction-maintenance regimen; desmoid data showed 62% ORR at 24 months and 72% ORR at 32 weeks.

4 source passages
So for investors who are getting still to know the Parabolus story, what is the core idea behind the Helicon platform and what does it enable you to do? And so we're very proud of that going into the phase three study that we're calling pedestal. And we're still committed to initiating that study in the first half next year. One is that we have agreed a dose and schedule regimen with FDA. So we were able to report at 24 months a 62% ORR, and at 32 weeks, we were able to see a 72% ORR. Open the document at this passage
Nov 5
Current report 8-K Events of Oct 30
Headquarters expansion begins January 1, 2028

Parabilis Medicines, Inc. amended its headquarters lease to add 33,525 square feet beginning January 1, 2028, extend the term through December 31, 2037, and provide an option for two additional five-year periods.

Entered into a material agreement
4 source passages
On October 30, 2026, Parabilis Medicines, Inc. (the “Company”) and LS 400/500 CDP, LLC (the “Landlord”) entered into a Third Amendment of Lease (the “Amendment”), which amends certain provisions of that certain Lease Agreement, by and between the Company and 400 Discovery Park, LLC, dated as of April 22, 2019, as amended (the “Lease”), regarding the Company’s corporate headquarters located at 30 Acorn Park Drive, Cambridge, Massachusetts (the “Existing Property”). The Amendment provides for, among other things: (i) an expansion, beginning on January 1, 2028, of the leased space by a total of 33,525 square feet on the first and sixth floors of the annexed building at 20 Acorn Park Drive (the “Neighboring Property” and, together with the Existing Property, the "Premises") with rent commencing on January 1, 2029, (ii) an amendment to the Company’s existing right of first offer, subject to certain conditions, to lease certain other space at the Neighboring Property as and when such space becomes available, and (iii) options, subject to certain conditions, to expand the Lease to cover certain additional space at the Premises. Pursuant to the Amendment, the term of the Lease is extended for an additional period, commencing on March 1, 2031 and expiring on December 31, 2037 (the “Extension Term”). The Amendment provides that the Company will have an option to further extend the term of the Lease for two additional five-year periods from the end of the Extension Term, subject to certain conditions. Open the document at this passage
Aug 13
Quarterly report 10-Q FY2026 Q2, ended Jun 30
Quarterly report for FY2026 Q2 AI summary on its way
Revenue $148K Net loss $52.46M Diluted EPS -$2.32
Showing 1–16 of 16 documents
Key facts CIK 1657677 CUSIP 698955101 13F (30d) 124 filings 124 filers Visit website Investor relations